Under the banner of a joint research and development, Novo Nordisk and US-based biotech firm 2Seventy Bio will develop a drug candidate for genetic bleeding disorder hemophilia A, reports a press release from 2Seventy Bio.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Ambu, Coloplast and GN helped by relaxation of China's covid policy
The three firms, which all have production facilities in the country, appear to be benefitting from the relaxation of China’s zero-tolerance Covid-19 policy.
Sonova completes Hysound Group acquisition, strengthens presence in China
The hearing aid giant now owns over 200 hearing clinics in China.
Extra data boosts Lundbeck's agitation case
Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.
FDA confirms rejection of Y-mabs' cancer drug
The US Food and Drug Administration has officially rejected a Y-mabs cancer drug, after it was voted down by a sub-committee in October.
Top news from MedWatch this week
Miss anything?
(Senior) CMC Project Manager 
Quality Compliance Specialist - Herbal Medicines and Medical Devices 
Laboratory assistants for an exciting QC department 
Strategic advisor and negotiator with in-depth knowledge of the pharmaceutical market 
Chief consultant for Dansk Erhvervs Health and life science 
Head Of Business Unit Pharma, Öresund Region, AFRY 
Nordic Medical Manager, Central Nervous System 
External Manufacturing Leads 
Principal Systems Engineer 
Associate Director, Global Drug Safety and Pharmacovigilance Scientist 
Supply Chain Manager